International Journal of Information Technology & Computer Engineering
ISSN 2347–3657
Volume 13, Issue 3, 2025

Automated Alzheimer's Detection Using Deep Learning And Mri Analysis

[1]Atiya Fatima – 24n81d5804
[2]Dr.V.S.Giridhar Akula,[3]Dr. Kaja Mastan,
Department Of Computer Science And Engineering
Sphoorthy Engineering College
Approved By Aicte, Affiliated To J.N.T.U, Hyderabad
2024-2025

ABSTRACT

A wide range of cognitive impairment symptoms are included in dementia, with Alzheimer's disease making up around two-thirds of cases. Alzheimer's disease currently has no known cure, therefore economic, financial, and medical repercussions can be avoided by early identification and aggressive care. To categorize the various phases of Alzheimer's disease, we provide a deep learning method in this work. First, we preprocess utilizing a pyramid example and bi-linear interpolation as part of our four-step technique. The feature extraction process then uses both the local binary pattern (LBP) and gray-level co-occurrence matrix (GLCM) approaches. After the characteristics are recovered, the VGG19 neural network is used to concatenate and classify them.

By using the Alzheimer's Disease Neuroimaging Initiative's (ADNI) MPRAGE structural MRI dataset, our approach outperformed current state-of-the-art technologies. With an overall accuracy of 89.80%, the suggested method successfully differentiated between gray matter (GM) and white matter (WM) across a number of diagnostic categories, including cognitively normal (CN), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and Alzheimer's disease (AD). Both GM and WM demonstrated good accuracy in binary classification tests. In particular, GM distinguished between CN and EMCI with 96.43% accuracy, EMCI and AD with 90.91% accuracy, and LMCI and AD with 95.24% accuracy. The accuracy of WM's categorization between CN and LMCI and between EMCI and LMCI was 95.6%. In certain comparisons, GM and WM both obtained the same 96.15% accuracy.

1.INTRODUCTION

Approximately 60–70% of dementia cases are caused by Alzheimer's disease. Among the signs that characterize dementia, the most noticeable is a gradual loss of cognitive function that surpasses the typical aging process. This deterioration may impact logical thinking, focus, memory, learning, arithmetic abilities, language, understanding, and decision-making, among other areas. People's ability to properly control their emotions, relationships, actions, and urges becomes more crucial as their cognitive capacities decline. Of the 50 million individuals with dementia who are 60 years of age or older worldwide, around 60% live in low- and middle-income nations. This figure is expected to increase to 82 million by 2030 and to 150 million by 2050, according to WHO projections. Global physical, mental, and emotional health will be significantly impacted by such a sharp rise. For instance, it is projected that the United States alone spent $818 billion on dementia-related healthcare and social assistance in 2015.

Usually starting with minor symptoms, dementia is a degenerative illness that eventually results in severe cognitive impairment. Three phases are frequently used to characterize the progression, which may be generally separated into the first two years, the next five years, and the time following that. "Healthy controls" (HC) or "cognitively normal" (CN) are some of the terminology used by researchers to categorize these stages; "mild cognitive impairment" (MCI) is used for the intermediate phase, and "advanced Alzheimer's disease" (AD) is used for the latter phase.

Throughout this process, a number of acronyms are often utilized. They may discuss the differences between early-onset (EO) and late-onset (LO) types of MCI, interpreters for persons with MCI-NC (mild cognitive impairment in non-converters), and those with mild to severe Alzheimer's or dementia. While stable moderate cognitive impairment (sMCI) describes situations in which symptoms do not noticeably increase over time, progressive mild cognitive impairment (pMCI) is linked to aging.

II. EXISTING SYSTEM

To categorize Alzheimer's disease, a number of existing systems use deep learning methods as transfer learning and convolutional neural networks (CNNs). By automatically identifying characteristics from brain MRI scans and classifying them into different phases of the disease, these methods have increased diagnosis accuracy. Even with these developments, there are still many obstacles to overcome. Large training datasets are necessary for many solutions, but they are hard to come by in medical imaging because of data scarcity and privacy issues. Furthermore, these systems usually need a significant amount of processing power, which makes them difficult to implement in settings with constrained hardware.

Some researchers have used pre-trained models, such those that were first learned on ImageNet, then refined them on smaller sets of brain MRI data in an effort to address these problems. Even while this approach can boost performance in situations with less data, it still has drawbacks such overfitting, decreased resilience, and a restricted capacity to generalize to new datasets.

ISSN 2347–3657

Volume 13, Issue 3, 2025

Among the main drawbacks of current systems are:
1. Limited precision: The inability of many current methods to classify Alzheimer's disease with high precision raises the possibility of incorrect diagnoses and treatment delays.
2. High data requirements: Large datasets, which are typically unavailable or challenging to get in medical situations, are sometimes necessary for effective training.
3. Computational demands: These models' high processing requirements make it difficult to use them in environments with limited resources.

III. PROPOSED SYSTEM

The Visual Geometry Group 19 (VGG19) convolutional neural network is used in the suggested method to analyze brain MRI images and categorize Alzheimer's illness. The system uses the pre-trained VGG19 architecture to identify different stages of Alzheimer's disease by extracting pertinent information from MRI data. Through fine-tuning VGG19 on a specific dataset of brain MRI images, our method leverages the model's shown efficacy in image classification and modifies it to meet the unique needs of Alzheimer's diagnosis.

There are several benefits to this setup. It can reduce the need for big training datasets, improve accuracy and efficiency in Alzheimer's stage classification, and remain resilient in the face of variations in picture quality and acquisition techniques. The system is able to provide trustworthy classifications and discern significant patterns from sparse MRI data by means of transfer learning and model refinement. This system has a huge potential impact. In the long run, it could improve patient outcomes by enabling early Alzheimer's disease identification and treatments. Furthermore, by providing unbiased information about the course of the disease, it can aid in clinical decision-making.

The ImageNet collection, which has millions of pictures in thousands of categories, was initially used to train VGG19. With its extensive collection of tagged photos, ImageNet is a comprehensive resource for visual object identification research. VGG19 is able to acquire generic visual characteristics by training on such a vast and varied dataset, which may be used to new applications such as medical picture analysis. The capacity of VGG19 to precisely extract and interpret characteristics from brain MRI images in the context of Alzheimer's disease classification is therefore improved by its ImageNet basis.

IV.RELATED WORK

In the past several years, deep learning methods have gained popularity for automatically identifying Alzheimer's disease using MRI images. Alzheimer's diagnosis has always relied on medical experts manually evaluating neuroimaging data, a laborious and open to subjective interpretation procedure. To overcome these constraints, scientists have resorted to deep learning and machine learning techniques that can accurately and effectively analyze massive amounts of imaging data.

In order to extract useful information from brain MRI images and classify people into groups like cognitively normal, moderate cognitive impairment (MCI), and Alzheimer's disease, convolutional neural networks, or CNNs, have become frequently used. By lowering the need for manual feature engineering, well-known CNN architectures like AlexNet, VGG, and ResNet have demonstrated exceptional performance in medical picture categorization. Furthermore, hybrid models that combine CNNs with Long Short-Term Memory (LSTM) or Recurrent Neural Networks (RNNs) have been developed to capture the temporal and spatial information seen in MRI sequences.

Some research have explored multimodal techniques beyond MRI-based analysis by combining MRI with additional data sources, such genetic information, cerebrospinal fluid (CSF) biomarkers, or PET scans, in order to improve diagnosis accuracy. A more thorough picture of the course of disease may be obtained by combining structural and functional brain data, as these multimodal frameworks show. Additionally popular is transfer learning, which refines models that have already been trained on large datasets for Alzheimer's detection, increasing efficiency and lowering training requirements.

Despite these developments, a number of issues still exist. There are still many obstacles to overcome, including class imbalance, dataset unpredictability, and poor generalizability to varied populations. Numerous research rely on benchmark datasets, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI), which could not accurately represent the variety of clinical situations encountered in the real world. Furthermore, interpretability is a challenge due to the opacity of deep learning models, as clinical decision-making requires doctors to have explicit and unambiguous explanations.

The substantial potential of deep learning in automating Alzheimer's detection is often highlighted by the corpus of relevant work. However, for these approaches to be widely used in clinical settings, more advancements in robustness, scalability, and interpretability are necessary.

V.SYSTEM MODEL

SYSTEM ARCHITECTURE



(a) Architecture of VGG19 model

International Journal of
Information Technology & Computer Engineering

ISSN 2347–3657

Volume 13, Issue 3, 2025

VI.Results and Discussions





VII . GRAPHS WITH EXPLANATION

International Journal of Information Technology & Computer Engineering
ISSN 2347–3657
Volume 13, Issue 3, 2025



The basis of the architecture for the Alzheimer's detection system is Convolutional Neural Networks (CNNs), which are the focus of deep learning techniques. Due to its ability to automatically learn spatial information from brain MRI pictures, CNNs are very useful in medical image analysis. CNNs recognize patterns—like alterations in brain anatomy, cortical thinning, and ventricle enlargement—that indicate the existence of Alzheimer's disease instead of relying on human created characteristics. Advanced architectures such as VGGNet, ResNet, DenseNet, and Inception have shown promise in identifying people with Alzheimer's disease (AD), mild cognitive impairment (MCI), or normal.



(a) Convolutional Neural Network (b) Recurrent Neural Network

To efficiently describe sequential information in medical imaging, several methods integrate Convolutional Neural Networks (CNNs) with Recurrent Neural Networks (RNNs), especially Long Short-Term Memory (LSTM) networks. LSTMs make it possible to capture relationships between these sequences since MRI data frequently consists of many slices or 3D volumes. Researchers may more precisely examine how a disease develops across several brain areas by employing CNNs to extract spatial information and LSTMs to simulate the temporal correlations.

Another popular method in this area is transfer learning. Here, Alzheimer's-specific datasets like the Alzheimer's Disease Neuroimaging Initiative (ADNI) are used to fine-tune deep learning models that have already been trained on huge datasets like VGG16 or ResNet50. When working with the restricted amount of data accessible in medical imaging as opposed to natural picture datasets, this method significantly improves performance and cuts down on training time. Through transfer learning, models may take use of information gathered from large datasets while adjusting to the particulars of MRI scans. In a number of research, CNN-extracted features are fed into conventional machine learning classifiers, including Support Vector Machines (SVMs), to determine the final diagnosis. SVMs are an excellent option when MRI sample numbers are constrained since they perform especially well on tiny and unbalanced datasets. Before classification, high-dimensional MRI data is compressed into more manageable representations using autoencoders for feature reduction and denoising.

Furthermore, immediately processing volumetric MRI data using 3D CNNs is increasingly used as an alternative to examining individual 2D slices. The ability of 3D CNNs to capture both spatial and structural interactions over the full brain volume sets them apart from ordinary CNNs and allows for a more thorough depiction of disease-related alterations. This feature enables 3D CNNs to be particularly successful in identifying minute structural anomalies linked to Alzheimer's disease in its early stages.

VIII. CONCLUSION

To sum up, we presented a technique that uses a sample pyramid approach and bi-linear interpolation to downscale MRI images by a factor of three. We used the Grey Level Co-Occurrence Matrix to evaluate four texture attributes: homogeneity, contrast, correlation,

ISSN 2347–3657

Volume 13, Issue 3, 2025

and entropy. The Local Binary Pattern approach was used to extract more information. By combining this data, we made multi-level categorization possible. Our methodology made use of a number of classification techniques, including attribute-based (AD), latent-variable (LMCI), binary (CN), and multi-class (EMCI). We divided MRI scans into Grey Matter (GM), White Matter (WM), and Cerebrospinal Fluid (CSF) when applied to the ADNI dataset, and we clearly displayed the results.

In binary classification tasks involving CN and EMCI, we found that GM had extraordinarily high accuracy, while in binary classification tasks involving CN and LMCI, we found that WM had great accuracy. Interestingly, GM and WM produced the same results for binary categorization for CN and AD. These results are promising for Alzheimer's disease early detection, indicating that our method may help lessen the effects of the illness and halt its progression.

IX. REFERENCES

[1] WHO. (2021). Dementia. [Online]. Available: https://www.who.int/newsroom/fact-sheets/detail/dementia.

[2] (2021). Alzheimer's Disease Fact Sheet. [Online]. Available: https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet.

[3] MayoClinic. (2021). Alzheimer's Disease. [Online]. Available: https://www.mayoclinic.org/diseasesconditions/alzheimersdisease/symptomscauses/syc-20350447.

[4] Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines, World Health Organization, Geneva, Switzerland, 2019.

[5] A. Rosenberg, F. Mangialasche, T. Ngandu, A. Solomon, and M. Kivipelto, "Multidomain interventions to prevent cognitive impairment, Alzheimer's disease, and dementia: From FINGER to world-wide FINGERS," J. Prevention Alzheimer's Disease, vol. 7, no. 1, pp. 29–36, 2020.

[6] M. Sado, A. Ninomiya, R. Shikimoto, B. Ikeda, T. Baba, K. Yoshimura, and M. Mimura, "The estimated cost of dementia in japan, the most aged society in the world," PLoS ONE, vol. 13, no. 11, Nov. 2018, Art. no. e0206508.

[7] A. Adlimoghaddam, B. Roy, and B. C. Albensi, "Future trends and the economic burden of dementia in manitoba: Comparison with the rest of Canada and the world," Neuroepidemiology, vol. 51, nos. 1–2, pp. 71–81, 2018.

[8] T. Ahonen and M. Pietikäinen, "Soft histograms for local binary patterns," in Proc. Finnish signal Process. Symp. (FINSIG), vol. 5, 2007, p. 1.

[9] D. Bredesen, The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline. Baltimore, MD, USA: Penguin, 2017.

[10] M. Sado, A. Ninomiya, R. Shikimoto, B. Ikeda, T. Baba, K. Yoshimura, and M. Mimura, "The estimated cost of dementia in japan, the most aged society in the world," PLoS ONE, vol. 13, no. 11, Nov. 2018, Art. no. e0206508.

[11] A. Adlimoghaddam, B. Roy, and B. C. Albensi, "Future trends and the economic burden of dementia in manitoba: Comparison with the rest of Canada and the world," Neuroepidemiology, vol. 51, nos. 1–2, pp. 71–81, 2018.

[12] T. Ahonen and M. Pietikäinen, "Soft histograms for local binary patterns," in Proc. Finnish signal Process. Symp. (FINSIG), vol. 5, 2007, p. 1.

[13] D. Bredesen, The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline. Baltimore, MD, USA: Penguin, 2017.

[14] P. M. Doraiswamy, L. P. Gwyther, and T. Adler, The Alzheimer's Action Plan: The Experts' Guide to the Best Diagnosis and Treatment for Memory Problems. New York, NY, USA: Macmillan, 2008.

[15] ASC (2021). Medical Tests for Diagnosing Alzheimer's. [Online]. Available: